Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.8% – Here’s Why

15 Sep 2026, 15:42 by Doug Wharley · The Cerbat Gem

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s stock price traded down 7.8% during mid-day trading on Tuesday . The stock traded as low as $12.37 and last traded at $12.1250. Approximately 128,976 shares changed hands during trading, a decline of 73% from the average daily volume of 469,739 shares. The stock had previously closed at $13.15.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on MPLT shares. Benchmark reaffirmed a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, June 22nd. Jefferies Financial Group reissued a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, July 27th. Wolfe Research restated an “outperform” rating and set a $30.00 price objective on shares of Maplight Therapeutics in a research report on Monday, July 27th. Raymond James Financial set a $31.00 target price on Maplight Therapeutics in a report on Friday, August 14th. Finally, Needham & Company LLC reduced their price target on shares of Maplight Therapeutics from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Four research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Get Our Latest Report on Maplight Therapeutics

Maplight Therapeutics Price Performance

The business has a 50 day simple moving average of $19.53 and a 200 day simple moving average of $23.80. The stock has a market cap of $565.00 million and a PE ratio of -0.29.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.08. As a group, sell-side analysts forecast that Maplight Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Insider Activity at Maplight Therapeutics

In other news, insider James Lillie sold 22,082 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the transaction, the insider owned 202,380 shares in the company, valued at $2,537,845.20. This represents a 9.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox purchased 15,620 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were acquired at an average price of $9.52 per share, for a total transaction of $148,702.40. Following the acquisition, the director directly owned 15,620 shares in the company, valued at $148,702.40. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Maplight Therapeutics

Several hedge funds have recently bought and sold shares of MPLT. Legal & General Group Plc bought a new position in shares of Maplight Therapeutics in the 2nd quarter valued at approximately $37,000. Bank of New York Mellon Corp boosted its position in Maplight Therapeutics by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock worth $802,000 after purchasing an additional 3,608 shares during the period. Wellington Management Group LLP boosted its position in Maplight Therapeutics by 12.4% during the second quarter. Wellington Management Group LLP now owns 51,917 shares of the company’s stock worth $1,861,000 after purchasing an additional 5,709 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Maplight Therapeutics during the second quarter valued at approximately $252,000. Finally, Deutsche Bank AG acquired a new position in Maplight Therapeutics in the 2nd quarter valued at $370,000.

About Maplight Therapeutics

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the central nervous system. The company’s research programs are aimed at addressing significant unmet needs in psychiatric and neurological diseases.

MapLight’s pipeline consists of investigational therapies designed to target biological pathways associated with conditions such as schizophrenia and other brain disorders. Its activities include drug discovery, clinical development and the evaluation of potential treatments through clinical trials.